Add Presentation to Slide Tray Presentation:
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Conclusions (1 of 2)
- The ability of medications to decrease fracture risk is most strongly established for postmenopausal women with osteoporosis (i.e., bone density scores in the osteoporosis range and/or pre-existing fractures).
- Bisphosphonates, denosumab, raloxifene, and teriparatide reduce vertebral fracture risk, but only alendronate, risedronate, zoledronic acid, and denosumab reduce hip fracture risk.
- Raloxifene does not reduce the risk of hip or nonvertebral fractures.
- Limited evidence supports a potential benefit for vitamin D and calcium (alone or in combination) in lowering fracture risk.
- Studies to date are inadequate to provide estimates of the benefits or harms of exercise.
Keywords: bisphosphonate | bone density | calcium | denosumab | exercise | fracture | hip | low bone density | osteopenia | osteoporosis | postmenopausal | raloxifene | risk | skeletal | teriparatide | vertebral | vitamin D | bone
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.